Haiyan Jiang

发表

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

J. Rasko, M. Kay, J. Zehnder, 2006, Nature Medicine.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice

R. Blumberg, D. Lillicrap, N. Josephson, 2015, Cellular immunology.

Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

M. Ozelo, J. Sommer, K. High, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Protection of Mammalian Cells from Severe Acute Respiratory Syndrome Coronavirus Infection by Equine Neutralizing Antibody

Wenda Gao, B. Ni, Yuzhang Wu, 2005, Antiviral therapy.

Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters.

B. Ni, Yuzhang Wu, Guangyu Zhao, 2007, Viral immunology.

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

J. Dumont, D. Quon, J. Sommer, 2012, Blood.

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020 .

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity

G. Toby, J. Sommer, G. Pierce, 2014, PloS one.

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

A. Bitonti, J. Dumont, L. Valentino, 2012, Blood.

The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.

R. Sarkar, Juan Li, Xiao Xiao, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.

V. Haurigot, H. Stedman, J. F. Wright, 2010, Blood.

Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.

G. Pierce, Haiyan Jiang, J. Kulman, 2015, Thrombosis research.

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.

A. Parker, J. F. Wright, L. Couto, 2003, Blood.

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

J. F. Wright, K. High, V. Arruda, 2007, Blood.

Population pharmacokinetics of recombinant factor VIII Fc fusion protein

I. Nestorov, M. Rogge, T. Ludden, 2015, Clinical pharmacology in drug development.

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice

A. Bitonti, G. Toby, J. Sommer, 2016, PloS one.

Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals.

J. Dumont, G. Pierce, Haiyan Jiang, 2015, Thrombosis research.

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

J. Sommer, G. Pierce, Haiyan Jiang, 2014, Thrombosis and Haemostasis.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

J. Dumont, D. Perry, L. Valentino, 2013, The New England journal of medicine.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B

I. Nestorov, J. Gobburu, T. Ludden, 2014, Clinical Pharmacokinetics.

Association Of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Hemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein

L. Valentino, A. Shapiro, G. Pierce, 2013 .

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

J. Dumont, I. Nestorov, D. Perry, 2014, Blood.

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

John E. Murphy, C. Pan, H. Tjandra, 2010, Blood.

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.

Ji-Yun Kim, J. Sommer, Junliang Pan, 2007, Blood.

Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.

J. Dumont, G. Pierce, Haiyan Jiang, 2015, Thrombosis research.

hemophilia A Phase 3 study of recombinant factor VIII Fc fusion protein in severe

J. Dumont, I. Nestorov, D. Perry, 2014 .

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

L. Couto, C. Scallan, Shangzhen Zhou, 2006, Blood.

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

A. Bitonti, J. Dumont, T. Nichols, 2012, Blood.

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.

H. Kazazian, R. Sarkar, A. Parker, 2003, Blood.

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

J. Dumont, S. Qiao, W. Lencer, 2015, Critical reviews in biotechnology.

Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo.

L. Santambrogio, E. Butcher, T. T. Dinh, 2016, Blood.

Discordant endothelial production of FVIII and vWF

L. Santambrogio, E. Butcher, T. T. Dinh, 2016 .

CD8+ T-cell responses to adeno-associated virus capsid in humans

Marcela V Maus, Hildegund C J Ertl, Haiyan Jiang, 2007, Nature Medicine.

The Bleeding Tendency In Relation To Predicted FVIII Activity Levels In Severe Hemophilia A Patients Treated With Recombinant Factor VIII Fc Fusion Protein

G. Pierce, Haiyan Jiang, Shuanglian Li, 2013 .

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes

Haiyan Jiang, D. Light, A. van der Flier, 2015, PloS one.

Site-Specific PEGylation of Factor VIII (PEG-FVIII) Preserves Full Clotting Activity and Extends Therapeutic Efficacy in HemophiliaA Dogs

John E. Murphy, D. Lillicrap, A. Labelle, 2008 .

Multi-year Therapeutic Benefit of AAV Serotypes 2, 6 and 8 Delivering Factor VIII to Hemophilia A Mice and Dogs Running Title: Long Term Liver-specific AAV-FVIII Therapy in Dogs

Morag, L. Couto, C. Scallan, 2006 .

Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020, Blood.

Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.

K. Hertogs, R. Clayton, M. Van Loock, 2009, Antiviral research.

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

J. Sommer, K. High, L. Couto, 2006, Blood.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

J. Sommer, L. Couto, C. Scallan, 2006, Blood.

Effects of transient immunosuppression on adeno associated virus- mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy Running Title: Immunosuppression in AAV8-hFIX treated macaques

J. Sommer, K. High, L. Couto, 2006 .

Different Contribution of Hematopoietic and Somatic Cell Types Expressing FcRn to the Prolonged Half-Life of Recombinant Factor VIII Fc and Recombinant FIX Fc

Haiyan Jiang, K. Wharton, D. Light, 2012 .

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo.

L. Santambrogio, E. Butcher, T. T. Dinh, 2016, Blood.

Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells.

K. Hertogs, R. Clayton, M. Van Loock, 2007, Journal of virological methods.

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

A. Bitonti, J. Dumont, L. Valentino, 2012, Blood.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Clinical-Scale Genome Editing of the Human BCL11A Erythroid Enhancer for Treatment of the Hemoglobinopathies

J. Stamatoyannopoulos, G. Stamatoyannopoulos, E. Rebar, 2015 .